ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
Previous Symbol
CUSIP16383L10
Phone650-210-2900
Debt
Debt-to-Equity Ratio0.69
Current Ratio2.87
Quick Ratio2.87
Price-To-Earnings
Trailing P/E Ratio26.25
Forward P/E Ratio-11.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$82.50 million
Price / Sales5.79
Cash Flow$0.3481 per share
Price / Cash27.15
Book Value$1.63 per share
Price / Book5.80
Profitability
EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net Margins13.88%
Return on Equity32.16%
Return on Assets6.49%
Miscellaneous
Employees66
Outstanding Shares50,530,000
Market Cap$513.85 million
OptionableOptionable
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx Inc (NASDAQ:CCXI) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The biopharmaceutical company earned $8.98 million during the quarter, compared to analysts' expectations of $11.55 million. ChemoCentryx had a return on equity of 32.16% and a net margin of 13.88%. View ChemoCentryx's Earnings History.
When is ChemoCentryx's next earnings date?
What price target have analysts set for CCXI?
6 brokerages have issued twelve-month price targets for ChemoCentryx's stock. Their forecasts range from $12.50 to $20.00. On average, they anticipate ChemoCentryx's stock price to reach $17.10 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price. View Analyst Price Targets for ChemoCentryx.
What is the consensus analysts' recommendation for ChemoCentryx?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 3 hold ratings, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.
What are Wall Street analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year end 2018 net cash of $2.49/ share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (8/13/2018)
- 2. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (7/16/2018)
Has ChemoCentryx been receiving favorable news coverage?
Headlines about CCXI stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ChemoCentryx earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Endocyte (ECYT), TESARO (TSRO), Pacira Pharmaceuticals (PCRX), Global Blood Therapeutics (GBT), Ironwood Pharmaceuticals (IRWD), AnaptysBio (ANAB), Reata Pharmaceuticals (RETA), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), Zogenix (ZGNX) and Innoviva (INVA).
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 59)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 55)
- Dr. Rajinder Singh, Sr. VP of Research (Age 51)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 65)
- Dr. Markus J. Cappel, Chief Bus. Officer & Treasurer (Age 57)
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.57%), Wasatch Advisors Inc. (4.75%), Franklin Resources Inc. (2.86%), Acadian Asset Management LLC (1.78%), Renaissance Technologies LLC (1.53%) and Dimensional Fund Advisors LP (1.08%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Plc Glaxosmithkline, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which institutional investors are selling ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., TIAA CREF Investment Management LLC, Virtus ETF Advisers LLC, Bridgeway Capital Management Inc., Strs Ohio and Keybank National Association OH. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Plc Glaxosmithkline, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.
Which institutional investors are buying ChemoCentryx stock?
CCXI stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Fosun International Ltd, Acadian Asset Management LLC, GSA Capital Partners LLP, Cadence Capital Management LLC, BlackRock Inc., Matarin Capital Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for ChemoCentryx.
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $9.45.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $513.85 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.
What is ChemoCentryx's official website?
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
